PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

BACKGROUND: The US Food and Drug Administration (FDA) has approved several immunotherapeutic drugs for cancer since 2010, and many more are still being evaluated in other clinical studies. These inhibitors significantly increase response rates and result in the treatment of patients with advanced ca...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Adv Res
Egile Nagusiak: Safi, Mohammed, Ahmed, Hyat, Al-Azab, Mahmoud, Xia, Yun-long, Shan, Xiu, Al-radhi, Mohammed, Al-danakh, Abdullah, Shopit, Abdullah, Liu, Jiwei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2020
Gaiak:
Medicine
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8020146/
https://ncbi.nlm.nih.gov/pubmed/33842004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jare.2020.09.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak